Brief: Xspray Q4 Revenue SEK 0
12/02/2025 07:00
Feb 12 (Reuters) - Xspray Q4 adjusted EPS SEK -2.36. * Q4 adjusted free cash flow SEK -61.601 million * Q4 pretax profit SEK -82.002 million
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003